DalCor Announces Data to be Presented at the American Heart Association Scientific Sessions 2016 in New Orleans

Data expected to further elucidate genetically distinct mechanism of action of dalcetrapib in patients with AA genotype of ADCY9 gene

LONDON, November 10, 2016 – DalCor Pharmaceuticals today announced the key investigator in dalcetrapib trials, Jean-Claude Tardif, C.M., M.D., FRCPC, FACC, FAHA, FESC, will present data at the American Heart Association Scientific Sessions 2016 (AHA) during the Abstract Rapid Fire Session on Sunday, November 13, 2016 in New Orleans.

The data presented further dissects the mechanism of genotype-dependent benefits of dalcetrapib on atherosclerotic cardiovascular outcomes, high-sensitivity C-reactive protein (hs-CRP) and cholesterol efflux in patients with the AA genotype at polymorphism rs1967309 of the ADCY9 gene.

Details of the presentation are below:

Session: Abstract: Endothelium, Vascular Tone and Nitric Oxide
Time: Sunday, November 13, 2016, 4:20pm
Title: Adenylate Cyclase Type 9 (Adcy9) Regulates Vasomotor Tone in Mice
Presenter: Jean-Claude Tardif, C.M., M.D., FRCPC, FACC, FAHA, FESC
Location: Ernest N. Morial Convention Center, Science and Technology Hall, Basic Science Theater

About Dalcetrapib

Dalcetrapib is the first precision medicine cardiovascular drug to reach full scale development. Over 17,000 patients have participated in dalcetrapib clinical trials. A large, double blind cardiovascular (CV) study, dal- Outcomes, randomized over 15,000 patients already taking statins. The drug was well tolerated but the study results were globally neutral – there was no significant reduction in CV events in the dalcetrapib group. In 2012, investigators at the Montreal Heart Institute led by Professors Jean-Claude Tardif and Marie- Pierre Dubé found a significant association between the effects of dalcetrapib in altering CV events and the polymorphism at the rs1967309 location in the adenylate cyclase type 9 (ADCY9) gene. Patients with the AA genotype had a 39% reduction in CV events when treated with dalcetrapib compared to placebo, while GG patients had a 27% increase and AG patients had a neutral effect. This analysis was conducted in 5749 patients. Additional analyses of other studies also demonstrated reduced atherosclerosis in the AA population when treated with dalcetrapib. DalCor secured a worldwide exclusive license for dalcetrapib together with rights to the genetic marker for use with dalcetrapib and is sponsoring the dal-GenE study, which is planned to include 5,000 patients to prospectively confirm the results of the pharmacogenomic analysis in the dal-Outcomes study in a patient population with the AA genotype at the rs1967309 location in the ADCY9 gene.

About DalCor Pharmaceuticals

DalCor is developing precision treatments by genetically targeting patients that will derive clinical benefits. By integrating clinical and genetic insights, DalCor intends to deliver superior clinical cardiovascular outcomes. The company’s first development program, dalcetrapib, is intended to reduce cardiovascular events in a specific genetic subset of patients. DalCor Pharmaceuticals has offices in Montreal, San Mateo, Calif., Zug, Switzerland and Stockport, U.K. For more information, visit

DalCor Contacts:

DalCor Pharmaceuticals
Donald Black, M.D.
(609) 613-6637
[email protected]

Russo Partners
Matt Middleman, M.D.
(212) 845-4272
[email protected]